



**World Health
Organization**

**Consultation on Using Health Technology Assessment for Universal Health Coverage and
Reimbursement Systems
2-3 November 2015
Salle B**

Meeting aims

1. Provide an overview of the progress towards the World Health Assembly resolution
2. Establish the role of WHO in the global HTA landscape in terms of:
 - a. Technical guidance
 - b. Process guidance
3. Gain consensus on how to move the HTA agenda forward in a cohesive manner

Agenda

Monday 2 November 2015

Session 1: HTA at WHO

- | | |
|---------------|---|
| 9.00-9.15 | Opening remarks and objectives of the meeting Assistant Director General, Health Systems and Innovation (HIS), Dr Marie-Paule Kieny |
| 9.15-9.45 | Introduction of participants Information on administrative and logistic issues |
| 9.45-10.00 | HTA at WHO: The World Health Assembly Resolution and mandate Director, Essential Medicines and Health Products (EMP), Dr Kees De Joncheere |
| 10.00- 10.15 | HTA and Universal Health Coverage Director Health Systems Governance and Financing (HGF), Dr Agnes Soucat |
| 10.15 – 10.30 | Findings of WHO 2015 Global Survey on HTA by National Authorities Ms Adriana Velazquez Berumen, EMP |
| 10.30 – 11.00 | Coffee break |

Session 2: Needs of countries

Chair: Prof Hans Severens (the Netherlands)

11.00 – 12:30 What are the current needs of countries in developing and implementing HTA?

- Dr Martha Gyansa-Lutterodt, Ghana
- Prof Sudigdo Sastroasmoro, Indonesia
- Prof Fatima Suleman, South Africa
- Ms Marianela Castillo, Chile

12.30-13.30 Lunch break

Session 3: Standards and Methodological Guidance

Chair: Dr Martha Gyansa-Lutterodt (Ghana)

13:30- 13:50 WHO products that contribute to HTA
Dr Tessa Tan Torres Edejer, HGF/WHO

13:50-15:30 Specific standards and methodological guidance: what currently exists and what is needed

- EUNeHTA Guidelines - Dr Marina Cerbo
- Priority setting, equity and efficiency – Dr Jeremy Lauer, HGF/WHO
- Cost-effectiveness Thresholds - Dr Melanie Bertram, HGF/WHO
- Expenditure and utilization data – Prof Libby Roughead, Australia
- Patient input to HTA - Ms Alison Lightbourne, International Alliance of Patients' Organizations

15:30 – 16:00 Coffee break

Session 4: The landscape of international networks and funding agencies

Chair: Ms Adriana Platona (Australia)

16:00 – 17:30 Capacity development for evidence based decision-making and HTA – needs, experience and current plans

- Cochrane Collaboration - Dr David Tovey or Ms Sylvie de Haan
- PAHO experience – Mr Alexandre Lemgruber
- HTAsiaLink - Dr Jeonghoon Ahn
- Advance-HTA - Prof Panos Kanavos
- IDSi - Dr Kalipso Chalkidou
- An academic perspective- Prof Lou Garrison
- The OHE reports - Prof Adrian Towse/Prof Chris Henshaw
- The Global Fund - Dr Michael Borowitz

17.30-17.45 Summary of day one - Secretariat

18.00-19.00 Reception

Tuesday 3 November 2015

Session 5: National HTA Systems – options for systems, processes and structures

Chair: Dr Raoul Dinarvand (Iran)

- 9.00 - 9.30 Using HTA to define benefits packages - OECD review of experience in countries
Ms Valérie Paris, OECD
- 9.30 – 10.15 National systems for evidence based decision-making for UHC – examples of how they have developed
- Dr Steffan Crausaz, PHARMAC, New Zealand
 - Ms Mari Mathiesen, Estonian Health Insurance Fund, Estonia
 - Ms Kristin Helene Svanqvist, Norwegian Medicines Agency, Norway
 - Dr Augusto Guerra, CCATES, Brazil
- 10.15- 10.30 Discussion
- 10.30-11.00 Coffee break

Session 6: Process Guidance

Chair: Prof Fatima Suleman (South Africa)

- 11:00-11.30 Pathways to building evidence-informed decision making to strengthen health systems – Preliminary framework for discussion.
Dr Kiu Tay-Teo, EMP
- 11.30 -12.30 Small group discussion:
What guidance needs to be developed and by what organisations? Process vs methods?
What structures and processes need to be put in place to ensure capacity development?
What are the roles and responsibilities of different stakeholders?
How can we avoid duplication but enhance coordination?
- 12.30-13.30 Lunch break

Session 7: Looking ahead – what is needed?

Chair: Prof Lou Garrison (USA)

- 13:30-14:30 Continue small group discussion
- 14.30 – 15.30 Report back
- 15.30-16.00 Coffee break

Session 8: Closing

Chair: Dr Kees de Joncheere, WHO

- 16.00-17.00 Secretariat summary of the meeting and proposed next steps
Dr Sue Hill
- 17.00 Closure of meeting